Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Sponsor: AstraZeneca
Summary
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
Official title: A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2025-05-26
Completion Date
2026-07-06
Last Updated
2026-07-01
Healthy Volunteers
No
Conditions
Interventions
AZD2389
Doses of AZD2389 will be administrated orally
PET scan and radioligand
PET scan and radioligand
Locations (1)
Research Site
Stockholm, Sweden